Drug Trial Radar · NCT04828616
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
104
Planned (sponsor's estimate)
Start
Jul 2021
Primary completion
Jul 2023
Study completion Jul 2024
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicentre, phase II study to evaluate the efficacy and safety of of DP303c injection in patients with HER2-expressing advanced ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
DP303c injectionDrug
DP303c injection, every 3 weeks (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR)Time frame: Through study completion, an average of 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.